The burgeoning popularity of retatrutide, initially for blood sugar control , is creating significant interest within the UK , prompting a notable shift in peptide trends. Access these compounds remains a complex situation , with NHS coverage currently limited and independent providers offering prescriptions at a substantial price. Concerns are bei